Semaglutide: A Promising Ally Against Alzheimer’s?
In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.
Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.
Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.
Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.
Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.
According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.
“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”
Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.
For more information, please contact Patty Zamora at [email protected].
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
After years of sharp increases and shrinking coverage options, Florida’s home insurance market is showing its strongest signs of recovery yet. Multiple insurers are proposing significant premium cuts for 2026 — some in the double digits — as storm‑loss data improves and private carriers re‑enter the state. Citizens Insurance is also seeking its first broad rate reduction in a decade, potentially lowering costs for millions of homeowners. This shift could boost affordability and confidence across Florida’s real estate and mortgage markets heading into the new year.
An AI company that began in a bedroom is now shaking the foundations of the lending industry. Salient, led by CEO Ari Malik, has skyrocketed to a $500 million valuation by fixing one of finance’s messiest problems: debt servicing. With zero customer churn, 100% pilot-to-contract conversions, and AI agents reportedly 30 times more compliant than humans, Salient is redefining how lenders manage loans. Its rapid rise highlights a new era where trust, regulation‑ready AI, and deep industry understanding are becoming essential for professionals across real estate, mortgage, finance, and insurance.
Redmond, Washington is tackling its housing crisis with Prisma, a six‑story, transit‑oriented development built on discounted surplus land from Sound Transit. The project will deliver 328 deeply affordable units—most reserved for households earning 50 percent of AMI or less, including families and people with disabilities. Enabled by a rare cross‑sector funding partnership, Prisma showcases how cities can combine transit investment, public resources, and private support to create long‑term, equitable housing solutions.
Citizens Property Insurance Corp. is recommending rate decreases for millions of Florida homeowners in 2026, marking the first potential premium drop in over a decade. If approved by state regulators, personal-line policies would fall an average of 2.6%, with some homeowners seeing reductions up to 11.5%. The shift reflects growing market stability driven by recent insurance reforms and increased private‑sector participation, though not all counties will benefit equally.
Despite alarming headlines, experts say AI isn’t the true driver behind Wall Street job cuts. Major banks like JPMorgan and Goldman Sachs are trimming staff, but economists point to post‑pandemic overhiring and economic uncertainty—not robots—as the real cause. While banks are investing heavily in AI tools, actual AI‑driven layoffs remain minimal. Instead, AI is slowing new hiring, reshaping roles, and pushing professionals across finance, real estate, and other industries to upskill rather than fear replacement.
Artificial intelligence is reshaping the real estate industry in 2025, powering a new surge of growth and maturity in the proptech sector. AI tools once considered experimental—such as predictive analytics, automated valuations, and digital transaction platforms—are now becoming essential to real estate, mortgage, insurance, and finance workflows. With rising investor confidence and widespread professional adoption, AI‑driven proptech is transforming how the industry operates and what skills modern professionals need to stay competitive.
